Leading orphan drugs based on R&D phase III cost 2015

This statistic displays the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.

Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

October 2015

Region

Worldwide

Survey time period

2015

Supplementary notes

* Projected top drugs based on NPV (net present value).

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Norway "

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.